{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:09:31Z","timestamp":1788307771180,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Increasing evidence suggests an association between SARS-CoV-2 vaccines and Guillain\u2013Barr\u00e9 syndrome (GBS). Nevertheless, little is understood about the contributing risk factors and clinical characteristics of GBS post SARS-CoV-2 vaccination. In this prospective surveillance study of 38,828,691 SARS-CoV-2 vaccine doses administered from February 2021 to March 2022 in the Gyeonggi Province, South Korea, 55 cases of GBS were reported post vaccination. We estimated the incidence rate of GBS per million doses and the incidence rate ratio for the vaccine dose, mechanism, age, and sex. Additionally, we compared the clinical characteristics of GBS following mRNA-based and viral vector-based vaccinations. The overall incidence of GBS following SARS-CoV-2 vaccination was 1.42 per million doses. Viral vector-based vaccines were associated with a higher risk of GBS. Men were more likely to develop GBS than women. The third dose of vaccine was associated with a lower risk of developing GBS. Classic sensorimotor and pure motor subtypes were the predominant clinical subtypes, and demyelinating type was the predominant electrodiagnostic subtype. The initial dose of viral-vector based vaccine and later doses of mRNA-based vaccine were associated with GBS, respectively. GBS following SARS-CoV-2 vaccination may not be clinically distinct. However, physicians should pay close attention to the classic presentation of GBS in men receiving an initial dose of viral vector-based SARS-CoV-2 vaccines.<\/jats:p>","DOI":"10.1038\/s41598-023-30940-1","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T06:04:33Z","timestamp":1678169073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Real-world data on the incidence and risk of Guillain\u2013Barr\u00e9 syndrome following SARS-CoV-2 vaccination: a prospective surveillance study"],"prefix":"10.1038","volume":"13","author":[{"given":"Jongmok","family":"Ha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunwook","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeeun","family":"Kyung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namoh","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Kyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeonjoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihoon","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Cheol","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang June","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euiho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom Seuk","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyoung","family":"Youn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Myoung","family":"Seok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunhee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"30940_CR1","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","volume":"5","author":"E Mathieu","year":"2021","unstructured":"Mathieu, E. et al. A global database of COVID-19 vaccinations. Nat. Hum. Behav. 5, 947\u2013953. https:\/\/doi.org\/10.1038\/s41562-021-01122-8 (2021).","journal-title":"Nat. Hum. Behav."},{"key":"30940_CR2","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher, A. et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N. Engl. J. Med. 384, 2092\u20132101. https:\/\/doi.org\/10.1056\/NEJMoa2104840 (2021).","journal-title":"N. Engl. J. Med."},{"key":"30940_CR3","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1001\/jama.2021.7517","volume":"325","author":"I See","year":"2021","unstructured":"See, I. et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA 325, 2448\u20132456. https:\/\/doi.org\/10.1001\/jama.2021.7517 (2021).","journal-title":"JAMA"},{"key":"30940_CR4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12974-021-02319-4","volume":"18","author":"NL Bragazzi","year":"2021","unstructured":"Bragazzi, N. L. et al. Global, regional, and national burden of Guillain\u2013Barr\u00e9 syndrome and its underlying causes from 1990 to 2019. J. Neuroinflammation 18, 264. https:\/\/doi.org\/10.1186\/s12974-021-02319-4 (2021).","journal-title":"J. Neuroinflammation"},{"key":"30940_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000430917","volume":"44","author":"WC Huang","year":"2015","unstructured":"Huang, W. C., Lu, C. L. & Chen, S. C. A 15-year nationwide epidemiological analysis of Guillain\u2013Barr\u00e9 syndrome in Taiwan. Neuroepidemiology 44, 249\u2013254. https:\/\/doi.org\/10.1159\/000430917 (2015).","journal-title":"Neuroepidemiology"},{"key":"30940_CR6","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/s0140-6736(12)62189-8","volume":"381","author":"DA Salmon","year":"2013","unstructured":"Salmon, D. A. et al. Association between Guillain\u2013Barr\u00e9 syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: A meta-analysis. Lancet 381, 1461\u20131468. https:\/\/doi.org\/10.1016\/s0140-6736(12)62189-8 (2013).","journal-title":"Lancet"},{"key":"30940_CR7","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.1980.03300500016019","volume":"243","author":"JS Marks","year":"1980","unstructured":"Marks, J. S. & Halpin, T. J. Guillain\u2013Barr\u00e9 syndrome in recipients of A\/New Jersey influenza vaccine. JAMA 243, 2490\u20132494 (1980).","journal-title":"JAMA"},{"key":"30940_CR8","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1016\/j.vaccine.2015.05.013","volume":"33","author":"LH Mart\u00edn Arias","year":"2015","unstructured":"Mart\u00edn Arias, L. H., Sanz, R., S\u00e1inz, M., Trece\u00f1o, C. & Carvajal, A. Guillain-Barr\u00e9 syndrome and influenza vaccines: A meta-analysis. Vaccine 33, 3773\u20133778. https:\/\/doi.org\/10.1016\/j.vaccine.2015.05.013 (2015).","journal-title":"Vaccine"},{"key":"30940_CR9","first-page":"288","volume":"32","author":"R Sanz Fadrique","year":"2019","unstructured":"Sanz Fadrique, R., Mart\u00edn Arias, L., Molina-Guarneros, J. A., Jimeno Bulnes, N. & Garc\u00eda Ortega, P. Guillain\u2013Barr\u00e9 syndrome and influenza vaccines: Current evidence. Rev. Esp. Quimioter 32, 288\u2013295 (2019).","journal-title":"Rev. Esp. Quimioter"},{"key":"30940_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10654-019-00596-1","volume":"35","author":"Y Chen","year":"2020","unstructured":"Chen, Y., Zhang, J., Chu, X., Xu, Y. & Ma, F. Vaccines and the risk of Guillain\u2013Barr\u00e9 syndrome. Eur. J. Epidemiol. 35, 363\u2013370. https:\/\/doi.org\/10.1007\/s10654-019-00596-1 (2020).","journal-title":"Eur. J. Epidemiol."},{"key":"30940_CR11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/s1473-3099(10)70140-7","volume":"10","author":"HC Lehmann","year":"2010","unstructured":"Lehmann, H. C., Hartung, H. P., Kieseier, B. C. & Hughes, R. A. Guillain\u2013Barr\u00e9 syndrome after exposure to influenza virus. Lancet Infect. Dis. 10, 643\u2013651. https:\/\/doi.org\/10.1016\/s1473-3099(10)70140-7 (2010).","journal-title":"Lancet Infect. Dis."},{"key":"30940_CR12","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/pds.3638","volume":"23","author":"J Prestel","year":"2014","unstructured":"Prestel, J. et al. Risk of Guillain\u2013Barr\u00e9 syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany. Pharmacoepidemiol. Drug Saf. 23, 1192\u20131204. https:\/\/doi.org\/10.1002\/pds.3638 (2014).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"30940_CR13","doi-asserted-by":"publisher","first-page":"e228879","DOI":"10.1001\/jamanetworkopen.2022.8879","volume":"5","author":"KE Hanson","year":"2022","unstructured":"Hanson, K. E. et al. Incidence of Guillain\u2013Barr\u00e9 syndrome after COVID-19 vaccination in the vaccine safety datalink. JAMA Netw Open 5, e228879. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.8879 (2022).","journal-title":"JAMA Netw Open"},{"key":"30940_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac067","author":"RYS Keh","year":"2022","unstructured":"Keh, R. Y. S. et al. COVID-19 vaccination and Guillain\u2013Barr\u00e9 syndrome: Analyses using the National Immunoglobulin Database. Brain J. Neurol. https:\/\/doi.org\/10.1093\/brain\/awac067 (2022).","journal-title":"Brain J. Neurol."},{"key":"30940_CR15","doi-asserted-by":"publisher","first-page":"e05733","DOI":"10.1002\/ccr3.5733","volume":"10","author":"Z Anjum","year":"2022","unstructured":"Anjum, Z. et al. Guillain\u2013Barr\u00e9 syndrome after mRNA-1273 (Moderna) COVID-19 vaccination: A case report. Clin. Case Rep. 10, e05733. https:\/\/doi.org\/10.1002\/ccr3.5733 (2022).","journal-title":"Clin. Case Rep."},{"key":"30940_CR16","doi-asserted-by":"publisher","first-page":"e13426","DOI":"10.7759\/cureus.13426","volume":"13","author":"S Waheed","year":"2021","unstructured":"Waheed, S., Bayas, A., Hindi, F., Rizvi, Z. & Espinosa, P. S. Neurological complications of COVID-19: Guillain\u2013Barre syndrome following Pfizer COVID-19 vaccine. Cureus 13, e13426. https:\/\/doi.org\/10.7759\/cureus.13426 (2021).","journal-title":"Cureus"},{"key":"30940_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/qjmed\/hcac102","volume":"115","author":"K Takahashi","year":"2022","unstructured":"Takahashi, K. et al. Guillain\u2013Barr\u00e9 syndrome after BNT162b2 (Pfizer-BioNTec) vaccination. QJM 115, 331\u2013333. https:\/\/doi.org\/10.1093\/qjmed\/hcac102 (2022).","journal-title":"QJM"},{"key":"30940_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/s1474-4422(21)00416-6","volume":"21","author":"JY Chun","year":"2022","unstructured":"Chun, J. Y. et al. Guillain\u2013Barr\u00e9 syndrome after vaccination against COVID-19. Lancet Neurol. 21, 117\u2013119. https:\/\/doi.org\/10.1016\/s1474-4422(21)00416-6 (2022).","journal-title":"Lancet Neurol."},{"key":"30940_CR19","doi-asserted-by":"publisher","first-page":"820723","DOI":"10.3389\/fneur.2021.820723","volume":"12","author":"JE Kim","year":"2021","unstructured":"Kim, J. E. et al. Guillain\u2013Barr\u00e9 syndrome and variants following COVID-19 vaccination: Report of 13 cases. Front. Neurol. 12, 820723. https:\/\/doi.org\/10.3389\/fneur.2021.820723 (2021).","journal-title":"Front. Neurol."},{"key":"30940_CR20","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","volume":"27","author":"M Patone","year":"2021","unstructured":"Patone, M. et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat. Med. 27, 2144\u20132153. https:\/\/doi.org\/10.1038\/s41591-021-01556-7 (2021).","journal-title":"Nat. Med."},{"key":"30940_CR21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","volume":"29","author":"JJ Sejvar","year":"2011","unstructured":"Sejvar, J. J. et al. Guillain\u2013Barr\u00e9 syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29, 599\u2013612. https:\/\/doi.org\/10.1016\/j.vaccine.2010.06.003 (2011).","journal-title":"Vaccine"},{"issue":"Suppl","key":"30940_CR22","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1002\/ana.410270707","volume":"27","author":"AK Asbury","year":"1990","unstructured":"Asbury, A. K. & Cornblath, D. R. Assessment of current diagnostic criteria for Guillain\u2013Barr\u00e9 syndrome. Ann. Neurol. 27(Suppl), S21-24. https:\/\/doi.org\/10.1002\/ana.410270707 (1990).","journal-title":"Ann. Neurol."},{"key":"30940_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","volume":"15","author":"SE Leonhard","year":"2019","unstructured":"Leonhard, S. E. et al. Diagnosis and management of Guillain\u2013Barr\u00e9 syndrome in ten steps. Nat. Rev. Neurol. 15, 671\u2013683. https:\/\/doi.org\/10.1038\/s41582-019-0250-9 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"30940_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/jnnp-2014-307815","volume":"86","author":"YA Rajabally","year":"2015","unstructured":"Rajabally, Y. A., Durand, M. C., Mitchell, J., Orlikowski, D. & Nicolas, G. Electrophysiological diagnosis of Guillain\u2013Barr\u00e9 syndrome subtype: Could a single study suffice?. J. Neurol. Neurosurg. Psychiatry 86, 115\u2013119. https:\/\/doi.org\/10.1136\/jnnp-2014-307815 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"30940_CR25","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jama.2021.15072","volume":"326","author":"NP Klein","year":"2021","unstructured":"Klein, N. P. et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA 326, 1390\u20131399. https:\/\/doi.org\/10.1001\/jama.2021.15072 (2021).","journal-title":"JAMA"},{"key":"30940_CR26","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1111\/ene.15504","volume":"29","author":"M Garc\u00eda-Grimshaw","year":"2022","unstructured":"Garc\u00eda-Grimshaw, M. et al. Incidence of Guillain\u2013Barr\u00e9 syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines. Eur. J. Neurol. 29, 3368\u20133379. https:\/\/doi.org\/10.1111\/ene.15504 (2022).","journal-title":"Eur. J. Neurol."},{"key":"30940_CR27","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/(sici)1097-0258(19970415)16:7<791::aid-sim500>3.0.co;2-#","volume":"16","author":"MP Fay","year":"1997","unstructured":"Fay, M. P. & Feuer, E. J. Confidence intervals for directly standardized rates: A method based on the gamma distribution. Stat. Med. 16, 791\u2013801. https:\/\/doi.org\/10.1002\/(sici)1097-0258(19970415)16:7%3c791::aid-sim500%3e3.0.co;2-# (1997).","journal-title":"Stat. Med."},{"key":"30940_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000324710","volume":"36","author":"JJ Sejvar","year":"2011","unstructured":"Sejvar, J. J., Baughman, A. L., Wise, M. & Morgan, O. W. Population incidence of Guillain\u2013Barr\u00e9 syndrome: A systematic review and meta-analysis. Neuroepidemiology 36, 123\u2013133. https:\/\/doi.org\/10.1159\/000324710 (2011).","journal-title":"Neuroepidemiology"},{"key":"30940_CR29","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/jns.12239","volume":"22","author":"JOT Sipil\u00e4","year":"2017","unstructured":"Sipil\u00e4, J. O. T., Soilu-H\u00e4nninen, M., Ruuskanen, J. O., Rautava, P. & Kyt\u00f6, V. Epidemiology of Guillain\u2013Barr\u00e9 syndrome in Finland 2004\u20132014. J. Peripher. Nerv. Syst. 22, 440\u2013445. https:\/\/doi.org\/10.1111\/jns.12239 (2017).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"30940_CR30","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/brain\/awy232","volume":"141","author":"AY Doets","year":"2018","unstructured":"Doets, A. Y. et al. Regional variation of Guillain\u2013Barr\u00e9 syndrome. Brain 141, 2866\u20132877. https:\/\/doi.org\/10.1093\/brain\/awy232 (2018).","journal-title":"Brain"},{"key":"30940_CR31","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/ana.26143","volume":"90","author":"BV Maramattom","year":"2021","unstructured":"Maramattom, B. V. et al. Guillain\u2013Barr\u00e9 syndrome following ChAdOx1-S\/nCoV-19 vaccine. Ann. Neurol. 90, 312\u2013314. https:\/\/doi.org\/10.1002\/ana.26143 (2021).","journal-title":"Ann. Neurol."},{"key":"30940_CR32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ana.26144","volume":"90","author":"CM Allen","year":"2021","unstructured":"Allen, C. M. et al. Guillain\u2013Barr\u00e9 syndrome variant occurring after SARS-CoV-2 vaccination. Ann. Neurol. 90, 315\u2013318. https:\/\/doi.org\/10.1002\/ana.26144 (2021).","journal-title":"Ann. Neurol."},{"key":"30940_CR33","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577 (2020).","journal-title":"N. Engl. J. Med."},{"key":"30940_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416. https:\/\/doi.org\/10.1056\/NEJMoa2035389 (2021).","journal-title":"N. Engl. J. Med."},{"key":"30940_CR35","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41591-022-01739-w","volume":"28","author":"L Chu","year":"2022","unstructured":"Chu, L. et al. Immune response to SARS-CoV-2 after a booster of mRNA-1273: An open-label phase 2 trial. Nat. Med. 28, 1042\u20131049. https:\/\/doi.org\/10.1038\/s41591-022-01739-w (2022).","journal-title":"Nat. Med."},{"key":"30940_CR36","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","volume":"386","author":"ED Moreira Jr","year":"2022","unstructured":"Moreira, E. D. Jr. et al. Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine. N. Engl. J. Med. 386, 1910\u20131921. https:\/\/doi.org\/10.1056\/NEJMoa2200674 (2022).","journal-title":"N. Engl. J. Med."},{"key":"30940_CR37","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/s0140-6736(21)01699-8","volume":"398","author":"A Flaxman","year":"2021","unstructured":"Flaxman, A. et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: A substudy of two randomised controlled trials (COV001 and COV002). Lancet 398, 981\u2013990. https:\/\/doi.org\/10.1016\/s0140-6736(21)01699-8 (2021).","journal-title":"Lancet"},{"key":"30940_CR38","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/jama.2021.24110","volume":"327","author":"ME Oster","year":"2022","unstructured":"Oster, M. E. et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA 327, 331\u2013340. https:\/\/doi.org\/10.1001\/jama.2021.24110 (2022).","journal-title":"JAMA"},{"key":"30940_CR39","doi-asserted-by":"publisher","first-page":"20963","DOI":"10.1038\/srep20963","volume":"6","author":"Y Che","year":"2016","unstructured":"Che, Y. et al. Circulating memory T follicular helper subsets, Tfh2 and Tfh17, participate in the pathogenesis of Guillain\u2013Barr\u00e9 syndrome. Sci. Rep. 6, 20963. https:\/\/doi.org\/10.1038\/srep20963 (2016).","journal-title":"Sci. Rep."},{"key":"30940_CR40","doi-asserted-by":"publisher","first-page":"6628","DOI":"10.3389\/fnagi.2020.613628","volume":"12","author":"KM Hagen","year":"2020","unstructured":"Hagen, K. M. & Ousman, S. S. The neuroimmunology of Guillain\u2013Barr\u00e9 syndrome and the potential role of an aging immune system. Front. Aging Neurosci. 12, 6628. https:\/\/doi.org\/10.3389\/fnagi.2020.613628 (2020).","journal-title":"Front. Aging Neurosci."},{"key":"30940_CR41","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature 586, 594\u2013599. https:\/\/doi.org\/10.1038\/s41586-020-2814-7 (2020).","journal-title":"Nature"},{"key":"30940_CR42","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","volume":"27","author":"KJ Ewer","year":"2021","unstructured":"Ewer, K. J. et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial. Nat. Med. 27, 270\u2013278. https:\/\/doi.org\/10.1038\/s41591-020-01194-5 (2021).","journal-title":"Nat. Med."},{"key":"30940_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0165-5728(98)00053-8","volume":"87","author":"K Hohnoki","year":"1998","unstructured":"Hohnoki, K., Inoue, A. & Koh, C. S. Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha\/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. J. Neuroimmunol. 87, 27\u201332. https:\/\/doi.org\/10.1016\/s0165-5728(98)00053-8 (1998).","journal-title":"J. Neuroimmunol."},{"key":"30940_CR44","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41590-022-01212-3","volume":"23","author":"Y Lustig","year":"2022","unstructured":"Lustig, Y. et al. Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose. Nat. Immunol. 23, 940\u2013946. https:\/\/doi.org\/10.1038\/s41590-022-01212-3 (2022).","journal-title":"Nat. Immunol."},{"key":"30940_CR45","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1001\/jama.2021.5374","volume":"325","author":"J Chapin-Bardales","year":"2021","unstructured":"Chapin-Bardales, J., Gee, J. & Myers, T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA 325, 2201\u20132202. https:\/\/doi.org\/10.1001\/jama.2021.5374 (2021).","journal-title":"JAMA"},{"key":"30940_CR46","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","volume":"27","author":"J Barros-Martins","year":"2021","unstructured":"Barros-Martins, J. et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination. Nat. Med. 27, 1525\u20131529. https:\/\/doi.org\/10.1038\/s41591-021-01449-9 (2021).","journal-title":"Nat. Med."},{"key":"30940_CR47","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.medj.2021.12.004","volume":"3","author":"NKH Khoo","year":"2022","unstructured":"Khoo, N. K. H. et al. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients. Med. (N. Y.) 3, 104-118.e104. https:\/\/doi.org\/10.1016\/j.medj.2021.12.004 (2022).","journal-title":"Med. (N. Y.)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30940-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30940-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30940-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T06:11:24Z","timestamp":1678169484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30940-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["30940"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-30940-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2161509\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"assertion":[{"value":"13 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3773"}}